Meat Processing Firm Sizzles on Earnings Beat

A major meat processing firm’s stock is surging after posting strong earnings, a logistics company just reported solid growth, and a tiny biotech stock is skyrocketing 175% after FDA approval for its first-in-human trial. Read on to know all about it.

Disaster Recovery Play (Sponsored)

Could This Stock Be the Biggest Winner in Disaster Recovery?

Wildfires and hurricanes have left devastation in their wake—but one company is turning the chaos into a booming business.

With a $15M-$35M recovery contract in hand, this small-cap stock is processing high-value scrap metal critical for rebuilding efforts. A new shredder has doubled processing capacity, adding millions in revenue, while rising tariffs are fueling demand for domestic recycled metals.

Insiders are loading up on shares, and with the stock trading at just $0.42, the window for early investors won’t stay open for long.

Get the full details before the market catches on.

Futures 📈

What to Watch

Earnings:

• Palantir Technologies [PLTR]: Aftermarket

• NXP Semiconductors N.V. [NXPI]: Aftermarket

• Equity Residential [EQR]: Aftermarket

• Clorox Company  [CLX]: Aftermarket

• Everest Group [EG]: Aftermarket

• Healthpeak Properties [DOC]: Aftermarket

• AECOM [ACM]: Aftermarket

Economic Reports:

• Employment Cost Index [Q4]: 8:30 a.m.

• Personal Income (nominal) [Dec]: 8:30 a.m.

• Personal Spending (nominal) [Dec]: 8:30 a.m.

• Core PCE Index [Dec]: 8:30 a.m.

• Chicago Business Barometer (PMI) [Jan]: 9:45 a.m.

Veterinary Diagnostics

Idexx Labs’ Q4 Results Better Than Expected; Plans Canine Cancer Test Launch in March

Idexx Laboratories [IDXX] reported fourth-quarter earnings that exceeded analyst forecasts on both revenue and profit today. The veterinary diagnostics and technology firm’s net income of $216.1 million, or $2.62 per share, is up from $194.5 million, or $2.32 per share, in the same quarter last year. Excluding one-time charges, adjusted earnings are at $2.53 per share, surpassing Wall Street estimates of $2.40.

Revenue climbed to $954.3 million in the quarter, marking an increase from $901.6 million in the prior year and beating the anticipated $935.1 million. CEO Jay Mazelsky highlighted the company’s ongoing expansion and announced plans to introduce a canine lymphoma cancer screening test in the U.S. and Canada by late March.

Looking ahead, Idexx provided revenue guidance for 2025 in the range of $4.06 billion to $4.17 billion, aligning with analysts’ expectations of $4.14 billion. The company also projects full-year earnings per share between $11.74 and $12.24, slightly above the forecasted $11.94 per share.

With solid financial performance and a growing portfolio of veterinary diagnostics, Idexx remains well-positioned for continued growth in the coming year. Investors are closely watching its upcoming product launches and expansion strategies in the animal healthcare market.

Food Processing

Tyson Foods Reports Strong Q1 Results and Stock Surges

Tyson Foods’ [TSN] first-quarter earnings are above analyst expectations, with both earnings per share (EPS) and revenue coming in higher than forecasts. The company’s non-GAAP EPS of $1.14 is higher than estimates by $0.26. Revenue is at $13.62 billion, reflecting a 2.3% year-over-year increase and beating projections by $160 million.

The firm’s stock is up 4.3% in premarket trade.

For fiscal 2025, Tyson expects adjusted operating income between $1.9 billion and $2.3 billion. Revenue is projected to remain flat or increase by up to 1% compared to 2024. The company has allocated between $1.0 billion and $1.2 billion for capital expenditures, focusing on profit improvement initiatives and essential maintenance projects.

Tyson anticipates net interest expenses of approximately $375 million for the year, while liquidity is expected to remain above the $1.0 billion minimum target, with a current total of $4.5 billion as of December 28, 2024. Free cash flow is forecasted to range between $1.0 billion and $1.6 billion. The company also projects an adjusted effective tax rate of around 25% for the fiscal year.

With a strong start to 2025 and a steady financial outlook, Tyson remains focused on strategic investments and operational efficiencies to maintain profitability in a competitive market.

Elon’s Radical Plan (Sponsored)

The DOGE Agenda (Eight Stocks to Buy)

Every investor in America is trying to figure out what Musk will do in Washington, D.C., in the coming weeks.

One Boston-based think tank – who has studied Elon’s work for decades – is stepping forward to share what they’ve found.

They believe his TRUE plan is far more radical than anyone realizes. It could change the way you live, work, get paid, and collect Social Security…

...AND could make more people rich than all of Elon's previous ventures – PUT TOGETHER.

Full story here.

Logistics

Saia Reports Strong Q4 Sales Growth, Expects Solid 2025 Performance

Saia’s [SAIA] fourth-quarter results are better than expected, causing its shares to go up by 1% in early trading. The freight transportation company’s revenue of $789 million, reflecting a 5% year-over-year increase, is higher than analyst estimates of $777.3 million.

Earnings per share (EPS) is at $2.84, slightly above the projected $2.77 but down from $3.33 in the same quarter last year. The company’s operating margin is 12.9%, a drop from 15% a year ago due to higher expenses.

CEO Fritz Holzgrefe highlighted the company’s expansion efforts, noting that Saia opened 21 new terminals and relocated nine others during 2024, bringing its total to 214 across the U.S. The company also onboarded 1,300 new employees, reinforcing its commitment to service growth.

Looking ahead, analysts anticipate revenue growth of 8.5% over the next year, driven by continued demand in the freight transportation sector. Saia’s full-year earnings per share are expected to reach $13.51, representing a 14.2% increase.

HCW Biologics Inc. [HCWB] - Last Close: $0.28

HCW Biologics Inc. is a clinical-stage biopharmaceutical firm focused on innovative immunotherapies that tackle chronic inflammation to extend health span.

Its stock is up nearly 175% in premarket trading because the U.S. FDA has just cleared the company's Investigational NDA, which will let HCW Biologics initiate a first-in-human Phase 1 clinical trial for its drug HCW9302 in patients.

GH Research PLC [GHRS] - Last Close: $10.60

GH Research PLC is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological disorders.

The Phase 2b clinical trial for its lead candidate GH001 for TRD has just met both primary and secondary endpoints, which is causing this stock to skyrocket nearly 90% in premarket trade.

Triumph Group, Inc. [TGI] - Last Close: $18.74

Triumph Group, Inc., is a leading aerospace supplier of mission-critical engineered systems and proprietary components.

TGI’s shares are up more than 30% in premarket trading after announcing that it is being acquired by PE firms Warburg Pincus and Berkshire Partners in an all-cash transaction valued at approximately $3 billion, representing a premium of ~123% over the company's unaffected closing stock price.

Cryptocurrency (Sponsored)

Better than Bitcoin? (Top Crypto for Less Than $1)

Over the past 15 years, Bitcoin has outperformed stocks, bonds, and every other asset you could've bought.

Many predict 2025 will be an even bigger year—hitting $200,000 or higher. But there's a better way to profit from this new crypto rally.

Most people don't know about it...and yet it's returned over 1,000% in 4 months.

This could be the #1 way to invest in crypto in 2025.

Get full details here.

Everything Else

• Volkswagen and BMW shares slide as European carmakers brace for U.S. tariffs.

• Fintech firm GoCardless reported its first profitable month and plans for long-term growth.

• The equal pay case against Asda reaches a major milestone for shop workers.

• Tesla’s sales slump in France, adding to its European challenges.

• Fewer infections this winter could challenge Pfizer’s post-pandemic strategy.

• SoftBank to invest billions in AI automation through its partnership with OpenAI.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.